Advances in tumor-infiltrating B lymphocytes

Yule Zhang; Ming Huang; Jinxiu Chen; Chunyu Cao; Hongyan Wu

doi:10.5114/ceji.2025.150659

eISSN: 1644-4124
ISSN: 1426-3912

Central European Journal of Immunology

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge

Editorial System

Submit your Manuscript

2/2025
vol. 50

Send email

Copy url:

abstract:

Review paper

Advances in tumor-infiltrating B lymphocytes

Yule Zhang

¹

,

Ming Huang

¹

,

Jinxiu Chen

¹

,

Chunyu Cao

^{1, 2, 3}

,

Hongyan Wu

^{1, 2, 3}

College of Basic Medical Science, China Three Gorges University, China
Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, China
Institute of Infection and Inflammation, China Three Gorges University, China

Cent Eur J Immunol 2025; 50 (2): 124-134

DOI: https://doi.org/10.5114/ceji.2025.150659

Online publish date: 2025/05/20

View full text Get citation

PlumX metrics:

In the landscape of tumor immunotherapy, T cell-mediated immune responses have consistently captured the attention, while the contributions of B cells have been neglected. Nevertheless, growing evidence underscores the pivotal role of tumor-infiltrating B cells and plasma cells, collectively termed tumor-infiltrating B lymphocytes (TIL-B), in cancer treatment. These cells not only contribute significantly to therapeutic outcomes and prognostication in the realms of standard treatment and immune checkpoint inhibition but also open avenues for novel immunotherapeutic strategies. Interestingly, the heterogeneity within TIL-B populations, marked by diverse phenotypic subgroups, provides them with the capacity to exert both antitumor and protumor influences. Therefore, a comprehensive understanding of TIL-B interactions with tumors would be helpful for harnessing TIL-B as targets in tumor immunotherapy. Here, we survey the current state of TIL-B research with the aim of elucidating their role in tumor immunotherapy and offering insights for the development of TIL-B-based therapeutic approaches.

keywords:

Advances in tumor-infiltrating B lymphocytes

Yule Zhang 1 , Ming Huang 1 , Jinxiu Chen 1 , Chunyu Cao 1, 2, 3 , Hongyan Wu 1, 2, 3

prognosis, immunotherapy, clinical significance, tumor-infiltrating B lymphocyte, tertiary lymphoid structure

Yule Zhang

¹

,

Ming Huang

¹

,

Jinxiu Chen

¹

,

Chunyu Cao

^{1, 2, 3}

,

Hongyan Wu

^{1, 2, 3}